ADB-P7AICA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first identified by the DEA in early 2021.[1][2]

ADB-P7AICA
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
Identifiers
  • N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-pentylpyrrolo[2,3-b]pyridine-3-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H28N4O2
Molar mass344.459 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)c1cn(CCCCC)c2ncccc21)C(C)(C)C
  • InChI=1S/C19H28N4O2/c1-5-6-7-11-23-12-14(13-9-8-10-21-17(13)23)18(25)22-15(16(20)24)19(2,3)4/h8-10,12,15H,5-7,11H2,1-4H3,(H2,20,24)(H,22,25)/t15-/m1/s1
  • Key:QDZHLYBDQFZWCJ-OAHLLOKOSA-N

See also

edit

References

edit
  1. ^ "Announcement of a Newly Identified Synthetic Cannabinoid ADB-P7AICA" (PDF). Drug Enforcement Administration Toxicology Testing Program. U.S. Department of Justice. 22 February 2021.
  2. ^ Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, et al. (February 2022). "Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA". RSC Medicinal Chemistry. 13 (2): 156–174. doi:10.1039/d1md00242b. PMC 8864554. PMID 35308023.